BioMarin Pharmaceutical
PUBLIC
STATUS
1K-5K
EMPLOYEES
BMRN
STOCK SYMBOL
13
INVESTMENTS
$83.16
SHARE PRICE
(As of Thursday Closing)
Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
Primary Industry
Therapeutic Devices
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
- 105 Digital Drive
- Novato, CA 94949
- United States
+1 (415) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore BioMarin Pharmaceutical’s full profile, request a free trial.
BioMarin Pharmaceutical Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $79.13 - $106.74 | $14.7B | $82.35 | -$0.44 | 1M | 178M |
BioMarin Pharmaceutical Financials Summary
|
In Thousands,
USD |
TTM
31-Dec-2018
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 14,918,961 | 14,940,490 | 15,553,711 | 14,317,106 |
| Revenue | 1,491,212 | 1,491,212 | 1,313,646 | 1,116,854 |
| EBITDA | (29,811) | (29,811) | 76,115 | (705,493) |
| Net Income | (77,211) | (77,211) | (117,042) | (630,210) |
| Total Assets | 4,427,128 | 4,427,128 | 4,633,125 | 4,023,690 |
| Total Debt | 830,417 | 830,417 | 1,174,470 | 683,239 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
BioMarin Pharmaceutical Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore BioMarin Pharmaceutical‘s full profile, request access.
Request full access to PitchBookBioMarin Pharmaceutical Investments & Acquisitions (13)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 000000 & 000 | 01-Oct-2015 | 000000000 00000 00 | 00000 | Other Business Products and Services | 0000-0000000 00000000 |
| 00000000 | 29-Jan-2015 | 000000000000000000 | 00000 | Biotechnology | 0000-0000000 00000000 |
| 00000000 000000000 | 07-Jan-2013 | 000000000000000000 | 00000 | Pharmaceuticals | |
| 000000 (000000000 | 01-Aug-2011 | 000000000 00000 00 | 000.00 | Buildings and Property | 0000-0000000 00000000 |
| ZyStor Therapeutics | 17-Aug-2010 | Merger/Acquisition | 00000 | Biotechnology | 0000-0000000 00000000 |
BioMarin Pharmaceutical Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00 00000 000000000 | 16-Jan-2009 | 0000 | 00.00 | Completed |
|
BioMarin Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore BioMarin Pharmaceutical‘s full profile, request access.
Request full access to PitchBookBioMarin Pharmaceutical Executive Team (19)
7 Former Executives
You’re viewing 5 of 19 executives. Get the full list »BioMarin Pharmaceutical Board Members (14)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alan Lewis Ph.D | Self | Board Member | 000 0000 | |
| Bryan Lawlis Ph.D | Self | Board Member | 000 0000 | |
| Dennis Slamon Ph.D | BioMarin Pharmaceutical | Board Member | 000 0000 | |
| Elaine Heron Ph.D | Self | Board Member | 000 0000 | |
| Jean-Jacques Bienaime | BioMarin Pharmaceutical | Chief Executive Officer & Chairman | 000 0000 |
5 Former Board Members
You’re viewing 5 of 14 board members. Get the full list »